Gene activity predicts course of chronic leukemia

Share this article:

A newly identified molecular marker quickly helps to distinguish whether a person with chronic lymphocytic leukemia (CLL) has a more aggressive or less aggressive form of the disease, information that guides treatment decisions.

As John C. Byrd, MD, of the Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Solove Research Institute in Columbus, Ohio, and colleagues noted in Journal of Clinical Oncology (http://jco.ascopubs.org/content/early/2012/05/03/JCO.2011.39.3090.abstract), increased expression of the ZAP-70 gene is known to predict poor prognosis in CLL. However, current methods for accurately measuring ZAP-70 are expensive and difficult to perform.

The investigators used a mass spectroscopy-based technique to analyze DNA methylation of the entire ZAP-70 gene regulatory regions in 247 CLL samples taken from patients participating in four different clinical studies. Methylation influences how much protein is produced by ZAP-70 and other genes. Byrd's group hypothesized that changes in ZAP-70 methylation status could explain decreases in ZAP-70 expression and a more favorable clinical outcome.

The researchers were able to identify a small area in one regulatory region of the ZAP-70 gene that showed large variability in methylation in CLL samples while being universally methylated in normal B cells.

The results demonstrated that patients are likely to have the slow-progressing form of CLL when the ZAP-70 gene is methylated in leukemia cells, and likely to have aggressive disease when the gene is unmethylated. In the latter group of patients, clinicians should consider beginning treatment immediately.     

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Presence of uterine cancers examined among women at the time of hysterectomy ...

Among women undergoing a minimally invasive hysterectomy using electric power morcellation, uterine cancers were present in 27 per 10,000 women at the time of the procedure, according to a new study.

New approach identifies cancer mutations as targets of effective melanoma immunotherapy

A new approach demonstrated that the recognition of unique cancer mutations appeared to be responsible for complete cancer regressions in two metastatic melanoma patients treated with a type of immunotherapy.

No change seen in breast cancer detection despite increased Medicare costs for ...

Breast cancer screening costs for Medicare patients skyrocketed between 2001 and 2009, but the increase did not lead to earlier detection of new breast cancer cases, according to a study.